Manning & Napier Group LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Manning & Napier Group LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145,447 shares of the medical research company's stock after buying an additional 2,453 shares during the quarter. Manning & Napier Group LLC's holdings in Thermo Fisher Scientific were worth $77,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Phoenix Holdings Ltd. grew its position in shares of Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company's stock valued at $4,750,000 after purchasing an additional 1,654 shares in the last quarter. DMC Group LLC raised its stake in shares of Thermo Fisher Scientific by 16.5% during the third quarter. DMC Group LLC now owns 592 shares of the medical research company's stock valued at $300,000 after acquiring an additional 84 shares in the last quarter. Montchanin Asset Management LLC raised its stake in Thermo Fisher Scientific by 1.1% in the second quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company's stock worth $2,374,000 after buying an additional 50 shares in the last quarter. Check Capital Management Inc. CA purchased a new position in Thermo Fisher Scientific in the third quarter worth $219,000. Finally, Tower Bridge Advisors grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company's stock valued at $16,727,000 after buying an additional 155 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $1.84 on Friday, hitting $581.21. The stock had a trading volume of 1,081,545 shares, compared to its average volume of 1,473,417. The firm's 50 day moving average price is $565.87 and its 200-day moving average price is $520.64. The company has a market capitalization of $221.62 billion, a price-to-earnings ratio of 37.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analysts' expectations of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $5.40 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.10%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMO. TheStreet upgraded shares of Thermo Fisher Scientific from a "c+" rating to a "b-" rating in a research report on Friday, December 22nd. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target for the company. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Barclays lowered shares of Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and increased their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Robert W. Baird restated an "outperform" rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $599.00.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the firm's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 over the last ninety days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.